A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
PXD101-301-G
NCT00131261
January 2005
June 2007
Name | Location |
---|---|
Northwestern University | Chicago, Illinois 60611 |
H. Lee Moffitt Cancer Center | Tampa, Florida 33612 |
James Berenson, MD, Inc | West Hollywood, California 90069 |
Research Facility | New York, New York 10021 |